The Prescription Drug Monitoring Program’s mission is to collect and provide, by electronic means, access to controlled substance prescription data and other relevant data for the purpose of providing information to various stakeholders to promote the proper prescribing, dispensing and utilization of medications in Connecticut.

The Prescription Monitoring Program collects prescription data for Schedule II through Schedule V drugs into a centralized database, the Connecticut Prescription Monitoring and Reporting System (CPMRS), which can then be used by healthcare providers and pharmacists in the active treatment of their patients. The purpose of the CPMRS is to present a complete picture of a patient’s controlled substance use, including prescriptions by other providers. As a healthcare tool, the CPMRS is used to improve quality of patient care and to reduce prescription abuse, opioid use disorder, and overdose. This allows providers the opportunity to properly manage the patient’s treatment, including referral of a patient to services offering treatment for substance use disorders when appropriate.  

CPMRS Integration is available at NO COST* to our users!

Streamline your workflow. Save Time. Focus on Patient Care.

The CPMRS can now be accessed through approved electronic health records (EHR) and pharmacy management systems (PMS) where PDMP data and NarxCare analytics will be delivered directly into your workflow. The Connecticut Prescription Monitoring Program (PMP) is pleased to announce a statewide initiative to integrate the CPMRS into approved EHR/PMS using Appriss Health’s PMP Gateway service.

For more information, navigate to CPMRS Integration to take advantage of the opportunity. For a limited of time, the *initial set-up fee and *user fees will be waived due to funding from the Centers for Medicare & Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS).

**2022 Updates**

• Public Act 22-81. No later than January 1, 2023, each pharmacy shall post a sign notifying consumers that they may visit the Department of Consumer Protection website for information concerning the safe storage of prescription drugs and the disposal of unused and expired prescription drugs. To download materials, click here.

• Public Act 22-108. Effective July 1, 2022, practitioners with a Controlled Substance Registration may transport Schedule II through V controlled substances from the location where they are registered to treat a patient. To do so, you must indicate on your Controlled Substance Registration that you intend to transport medications that are designated as Schedule II through V controlled substances from the address you provided for your controlled substance registration to another location for the purpose of treating a patient.

**2021 Updates**

• Public Act 21-182. Effective June 28, 2021, veterinarians, licensed under chapter 384, are exempt from the reporting requirement for the dispensation of insulin drugs, glucagon drugs, diabetes devices, and diabetic ketoacidosis devices for animal patients.
• Public Act 21-192. Effective July 1, 2022, federal Substance Abuse and Mental Health Services Administration certified substance use disorder clinics licensed under section 19a-495 in accordance with 42 CFR 2 will be mandated to report prescription information for dispensed schedules II, III, IV and V controlled substances to the prescription drug monitoring program.     
• Effective January 1, 2021, dispensation information for insulin drugs, glucagon drugs, diabetes devices, diabetic ketoacidosis devices, gabapentin, and naloxone are required to be uploaded into the CPMRS. All listed prescriptions will be available on patient reports except for naloxone. Only CPMRS admin will have access to naloxone data for the purpose of aggregate population analytics that will help to inform public policy. For more information, please visit the For Pharmacists webpage.